Copyright
©The Author(s) 2019.
World J Gastrointest Oncol. Aug 15, 2019; 11(8): 634-641
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Published online Aug 15, 2019. doi: 10.4251/wjgo.v11.i8.634
Table 1 Baseline characteristics of included patients [n = 33, n (%)]
| Age (yr) | 63 (41–80) |
| Sex | |
| Male | 28 (84) |
| Female | 5 (16) |
| WHO performance status | |
| 0 | 20 (60) |
| 1 | 13 (40) |
| Denutrition | |
| > 10% weight loss | 10 (30) |
| Localization | |
| Gastric | 15 (45) |
| Gastro-oesophageal junction Siewert I | 12 (35) |
| Gastro-oesophageal junction Siewert II | 3 (10) |
| Gastro-oesophageal junction Siewert III | 3 (10) |
| Surgery | |
| Lewis Santy | 11 (33) |
| Total Gastrectomy | 11 (33) |
| Subtotal Gastrectomy | 11 (33) |
| Clinical tumour stage | |
| cT3/T4 | 7 (81) |
| cT1/T2 | 5 (18) |
| cTx | 21 (1) |
| cN+ | 22 (77) |
| cN– | 8 (23) |
| Histological type | |
| Intestinal | 28 (84) |
| Singet Ring cells | 5 (16) |
| HER2 overexpressing | 5 (16) |
- Citation: Basso V, Orry D, Fraisse J, Vincent J, Hennequin A, Bengrine L, Ghiringhelli F. Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World J Gastrointest Oncol 2019; 11(8): 634-641
- URL: https://www.wjgnet.com/1948-5204/full/v11/i8/634.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v11.i8.634